Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
View Infographic
Infographic not yet available.
MRK Coverage
Event
Merck & Co., Inc. (MRK) FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
Mar 18, 2026
Event
Merck & Co., Inc. (MRK) Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Mar 17, 2026
Event
Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Feb 27, 2026
Transcript
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Feb 4, 2026
Transcript
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Oct 30, 2025
News
Infographic: How Merck (MRK) performed in Q3 2024
Oct 31, 2024